Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The efficacy and safety of exenatide once weekly in patients with type 2 diabetes

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Non-insulin pharmacological therapies for treating type 1 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Exenatide: pharmacokinetics, clinical use, and future directions

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Management of cardiovascular disease in patients with psoriasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Treatment with non-steroidal anti-inflammatory drugs in patients after myocardial infarction - a systematic review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Gluco-metabolic effects of pharmacotherapy-induced modulation of bile acid physiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Exenatide once weekly (QW) is a glucagon-like peptide 1 receptor agonist (GLP-1RA) that was approved in 2012 in Europe and the U.S.A. for the treatment of type 2 diabetes (T2D). Areas covered: This review provides an overview of the safety and efficacy of exenatide QW for the treatment of T2D and evaluates the benefit-risk ratio compared to other available long-acting GLP-1RAs. In addition, the authors provide an outline of the novel formulations and delivery methods of exenatide. Expert opinion: Exenatide QW is an efficacious and safe treatment for T2D. However, head-to-head trials have demonstrated exenatide QW to be inferior to liraglutide and semaglutide with respect to effects on fasting plasma glucose, glycated hemoglobin A1c, and bodyweight. In addition, exenatide QW appears inferior to liraglutide and semaglutide in terms of cardiovascular risk reduction. Currently, the overall risk-benefit profiles for the range of GLP-1RAs point to liraglutide and semaglutide as first-choice for the management of T2D, which has been confirmed by a recently published consensus report on the treatment of T2D from the American Diabetes Association and the European Association for the Study of Diabetes. The pricing of exenatide QW will most likely be a key determinant for its place in the future management of T2D.

OriginalsprogEngelsk
TidsskriftExpert Opinion on Pharmacotherapy
Vol/bind20
Udgave nummer5
Sider (fra-til)501-510
Antal sider10
ISSN1465-6566
DOI
StatusUdgivet - 2019

ID: 56500407